NextCure Inc NXTC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
-
Halper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders
-
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBK, and FHB
-
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
Trading Information
- Previous Close Price
- $6.58
- Day Range
- $6.59–7.22
- 52-Week Range
- $1.55–15.74
- Bid/Ask
- $5.55 / $7.42
- Shares Outstanding
- 4.58M
- Market Cap
- $31.49M
- Volume/Avg
- 1 / 362,305
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 40
- Website
- https://www.nextcure.com
Valuation
|
Metric
|
NXTC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.10 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NXTC
|
|---|---|
Quick Ratio | 3.13 |
Current Ratio | 3.47 |
Interest Coverage | — |
Quick Ratio
NXTC
Profitability
|
Metric
|
NXTC
|
|---|---|
Return on Assets (Normalized) | −78.03% |
Return on Equity (Normalized) | −119.72% |
Return on Invested Capital (Normalized) | −102.48% |
Return on Assets
NXTC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|sCvNxhm | LOCK|Gm&^ | $129B | |||
| Moderna Inc
MRNA
| LOCK|y&^C%xR | LOCK|z@ | $94B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|X!WXp$ | LOCK|c%!x | $82B | |||
| argenx SE ADR
ARGX
| LOCK|YzM?z# | LOCK|J^x | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Dys#&@ | LOCK|&# | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|kkHZp?Q | LOCK|@Bmj | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|CHrbb#Y | LOCK|Lr&# | $27B | |||
| Incyte Corp
INCY
| LOCK|M^jWQ? | LOCK|?>Q | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|>bw^lT | LOCK|%% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@Jq#NK | LOCK|W%< | $14B |
United States